Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus…
Adaptive Pre-Surgery Therapy for Patients with Localized Pancreatic Cancer
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Adding Focused Radiation to Standard Pancreatic Cancer Treatment
Researchers are using IORT--intraoperative radiation therapy--to treat pancreatic cancer that cannot be surgically removed.
My Most Challenging Race
Eric Lasner faced Whipple surgery, chemotherapy with FOLFIRINOX, and radiation, in order to get back to closed circuit road racing.
Comparing Effectiveness of Chemotherapy Before and After Surgery
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE), a minimally invasive surgical technique, makes it easier for chemotherapy to reach pancreatic cancer cells.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.